Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Bipolar Disorder, Schizoaffective Disorder, Manic Disorder
About this trial
This is an interventional treatment trial for Bipolar Disorder focused on measuring bipolar disorder, bipolar mania, schizoaffective disorder, schizoaffective mania, mania, kappa opiates, opiates
Eligibility Criteria
Inclusion Criteria:
- bipolar or schizoaffective disorder
- currently manic
- no acute medical issues
- no substance withdrawal
Exclusion Criteria:
- unable to give informed consent
- using opiates for pain management
- history of head injury, dementia, or mental retardation
- seizure disorder
- glaucoma
- unstable cardiac condition or arrhythmia
- moderate-severe pulmonary disease
- pregnancy
Sites / Locations
- McLean Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Pentazocine then Lorazepam
Lorazepam then Pentazocine
In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.